Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Baricitinib for Rheumatoid Arthritis
Recruiting3 awardsPhase 4
Philadelphia, Pennsylvania
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.